REGENXBIO Inc.
NASDAQ:RGNX
10.6 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 90.242 | 112.724 | 470.347 | 154.567 | 35.233 | 218.505 | 10.393 | 4.589 | 7.588 | 6.12 | 6.087 |
| Cost of Revenue
| 54.533 | 54.545 | 51.833 | 35.714 | 8.241 | 9.64 | 1.709 | 0.959 | 1.503 | 1.007 | 0.324 |
| Gross Profit
| 35.709 | 58.179 | 418.514 | 118.853 | 26.992 | 208.865 | 8.684 | 3.63 | 6.085 | 5.113 | 5.763 |
| Gross Profit Ratio
| 0.396 | 0.516 | 0.89 | 0.769 | 0.766 | 0.956 | 0.836 | 0.791 | 0.802 | 0.835 | 0.947 |
| Reseach & Development Expenses
| 214.946 | 242.453 | 181.437 | 166.294 | 124.185 | 83.873 | 57.224 | 45.482 | 17.279 | 4.961 | 5.051 |
| General & Administrative Expenses
| 88.494 | 85.281 | 79.333 | 63.817 | 51.815 | 36.85 | 27.229 | 23.59 | 11.912 | 3.851 | 5.474 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 88.494 | 85.281 | 79.333 | 63.817 | 51.815 | 36.85 | 27.229 | 23.59 | 11.912 | 3.851 | 5.474 |
| Other Expenses
| -0.397 | -6.679 | -2.236 | 7.975 | -0.01 | 0.042 | 0.116 | -0.102 | -0.026 | -0.047 | 0 |
| Operating Expenses
| 303.837 | 321.055 | 258.534 | 238.086 | 175.99 | 120.765 | 84.569 | 68.97 | 29.165 | 8.765 | 10.525 |
| Operating Income
| -268.128 | -262.876 | 159.98 | -119.233 | -148.998 | 88.1 | -75.885 | -65.34 | -23.137 | -3.682 | -4.776 |
| Operating Income Ratio
| -2.971 | -2.332 | 0.34 | -0.771 | -4.229 | 0.403 | -7.302 | -14.238 | -3.049 | -0.602 | -0.785 |
| Total Other Income Expenses Net
| 4.482 | -17.529 | -18.733 | 13.223 | 51.51 | 7.07 | 2.716 | 1.938 | 0.289 | -0.03 | -0.014 |
| Income Before Tax
| -263.646 | -280.405 | 141.247 | -106.01 | -97.488 | 104.116 | -73.169 | -63.402 | -22.811 | -4.003 | -5.387 |
| Income Before Tax Ratio
| -2.922 | -2.488 | 0.3 | -0.686 | -2.767 | 0.476 | -7.04 | -13.816 | -3.006 | -0.654 | -0.885 |
| Income Tax Expense
| -0.152 | -0.084 | 13.407 | 5.24 | -2.755 | 4.179 | 0.686 | -0.435 | -0.06 | 0.291 | 0.597 |
| Net Income
| -263.494 | -280.321 | 127.84 | -111.25 | -94.733 | 99.937 | -73.169 | -62.967 | -22.811 | -4.003 | -5.387 |
| Net Income Ratio
| -2.92 | -2.487 | 0.272 | -0.72 | -2.689 | 0.457 | -7.04 | -13.721 | -3.006 | -0.654 | -0.885 |
| EPS
| -6.02 | -6.5 | 3.01 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 | -2.49 | -0.3 | -0.41 |
| EPS Diluted
| -6.02 | -6.5 | 2.91 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 | -2.49 | -0.3 | -0.41 |
| EBITDA
| -250.808 | -262.534 | 160.699 | -114.962 | -197.557 | 81.03 | -78.601 | -65.34 | -23.08 | -3.652 | -4.762 |
| EBITDA Ratio
| -2.779 | -2.329 | 0.342 | -0.744 | -5.607 | 0.371 | -7.563 | -14.238 | -3.042 | -0.597 | -0.782 |